POLYCLONAL ANTIBODY MARKET ANALYSIS

Polyclonal Antibody Market, By Type (Primary Antibody, Secondary Antibody), By Source (Rabbits, Goats, Sheep, Others), By Application (Academic Research, Diagnostics, Others), By End User (Academic & Research Institutes, Pharmaceutical and Biotechnology Companies, Others), , By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In : Dec 2023
Code : CMI4347
Pages :190
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market News

Recent Developments

On January 5, 2023, SAB Biotherapeutics, Inc., a biotechnology company, announced positive results from a project in collaboration with CSL, a biotechnology company, confirming that SAB’s DiversitAb platform can generate functional fully-human anti-idiotype polyclonal antibodies that effectively target and neutralize autoantibodies associated with autoimmune diseases.

Collaborations

In March 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, initiated the development of Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), a plasma-derived therapy for treating infection in individuals caused due to COVID-19. Thus, these initiatives and collaborations are expected to propel market growth.